3/4-Optimizing Complicated Grief Therapy

3/4-优化复杂悲伤治疗

基本信息

项目摘要

DESCRIPTION (provided by applicant): This resubmission application is for competitive renewals of our prior grant (MH060783) in which we established the efficacy of a targeted complicated grief treatment (CGT). The current application is to conduct a multicenter study to take the next steps needed to optimize treatment for individuals suffering from complicated grief, and responds to PA-07-092 inviting grant applications for collaborative studies of mental disorders in adults. Complicated grief (CG) is a debilitating condition that is estimated to affect millions of people in the United States alone. Our prior study was the first RCT to address this condition. Participants in our study continued stable antidepressant medication while receiving CGT or Interpersonal Psychotherapy (IPT). Individuals taking antidepressants had better outcome in both treatments, though CGT was superior to IPT when administered with (60% responders v. 40%) or without (42% v. 19%) antidepressants. Studies of antidepressant medication alone have shown mixed results with SSRIs appearing to be promising. However, there has been no randomized controlled study of SSRIs for CG. Determining the efficacy of SSRI treatment for CG, when administered with and without CGT, is of great public health importance. We have assembled 4 groups of investigators with strong track records in bereavement research and extensive experience with intervention studies and multicenter projects, to conduct a study of escitalopram (ESC) efficacy. We plan to enroll 440 people with a primary diagnosis of Complicated Grief over 4.5 years, and to randomly assign them to receive 16 weeks of treatment with ESC, PBO, ESC + CGT or PBO + CGT. Specific aims are to compare 1) ESC v PBO, 2) ESC + CGT v PBO + CGT and 3) CGT + ESC v ESC on measures of responder status and on improvement in CG symptoms, depression, anxiety, functional impairment, sleep and suicidality. We will explore mediator and moderator hypotheses to answer questions about how these treatments work and who might benefit most from each approach. Answers to these questions have important public health significance.
描述(由申请人提供):本重新提交申请是为了对我们先前的批准(MH060783)进行竞争性续期,我们在该批准中确定了靶向复杂悲伤治疗(CGT)的有效性。目前的申请是开展一项多中心研究,以采取下一步需要的措施,以优化患有复杂悲伤的个人的治疗方法,并响应PA-07-092邀请成人精神障碍合作研究的资助申请。复杂悲伤(CG)是一种使人衰弱的疾病,据估计仅在美国就有数百万人受到影响。我们之前的研究是第一个针对这种情况的随机对照试验。本研究的参与者在接受CGT或人际心理治疗(IPT)的同时继续服用稳定的抗抑郁药物。服用抗抑郁药物的个体在两种治疗中都有更好的结果,尽管CGT在服用抗抑郁药物(60%对40%)或不服用抗抑郁药物(42%对19%)时优于IPT。抗抑郁药物单独的研究表明,与SSRIs的混合结果似乎很有希望。然而,目前尚无SSRIs类药物治疗CG的随机对照研究。确定SSRI治疗CG的疗效,无论是合并还是不合并CGT,都具有重要的公共卫生意义。我们召集了4组研究人员,他们在丧亲研究方面有良好的记录,在干预研究和多中心项目方面有丰富的经验,以开展艾司西酞普兰(ESC)疗效的研究。我们计划在4.5年内招募440名初步诊断为复杂悲伤的患者,并随机分配他们接受16周的ESC、PBO、ESC + CGT或PBO + CGT治疗。具体目的是比较1)ESC与PBO, 2) ESC + CGT与PBO + CGT和3)CGT + ESC与ESC对应答者状态的测量以及CG症状、抑郁、焦虑、功能障碍、睡眠和自杀倾向的改善。我们将探讨中介和调节假设,以回答有关这些治疗如何起作用以及谁可能从每种方法中获益最多的问题。这些问题的答案具有重要的公共卫生意义。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHARLES F. REYNOLDS其他文献

CHARLES F. REYNOLDS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHARLES F. REYNOLDS', 18)}}的其他基金

Preventing Depression in Later Life: A Model for Low and Middle Income Countries
预防晚年抑郁症:低收入和中等收入国家的典范
  • 批准号:
    8444157
  • 财政年份:
    2013
  • 资助金额:
    $ 34.66万
  • 项目类别:
Preventing Depression in Later Life: A Model for Low and Middle Income Countries
预防晚年抑郁症:低收入和中等收入国家的典范
  • 批准号:
    8740555
  • 财政年份:
    2013
  • 资助金额:
    $ 34.66万
  • 项目类别:
ACISR for Late-Life Depression Prevention
ACISR 预防晚年抑郁症
  • 批准号:
    8921247
  • 财政年份:
    2011
  • 资助金额:
    $ 34.66万
  • 项目类别:
ACISR for Late-Life Depression Prevention
ACISR 预防晚年抑郁症
  • 批准号:
    8101499
  • 财政年份:
    2011
  • 资助金额:
    $ 34.66万
  • 项目类别:
ACISR for Late-Life Depression Prevention
ACISR 预防晚年抑郁症
  • 批准号:
    8294567
  • 财政年份:
    2011
  • 资助金额:
    $ 34.66万
  • 项目类别:
ACISR for Late-Life Depression Prevention
ACISR 预防晚年抑郁症
  • 批准号:
    8465280
  • 财政年份:
    2011
  • 资助金额:
    $ 34.66万
  • 项目类别:
ACISR for Late-Life Depression Prevention
ACISR 预防晚年抑郁症
  • 批准号:
    8659200
  • 财政年份:
    2011
  • 资助金额:
    $ 34.66万
  • 项目类别:
1/3-Incomplete Response in Late-Life Depression: Getting to Remission
1/3-晚年抑郁症的不完全反应:走向缓解
  • 批准号:
    8102067
  • 财政年份:
    2009
  • 资助金额:
    $ 34.66万
  • 项目类别:
3/4-Optimizing Complicated Grief Therapy
3/4-优化复杂悲伤治疗
  • 批准号:
    8436293
  • 财政年份:
    2009
  • 资助金额:
    $ 34.66万
  • 项目类别:
1/3-Incomplete Response in Late-Life Depression: Getting to Remission
1/3-晚年抑郁症的不完全反应:走向缓解
  • 批准号:
    7899917
  • 财政年份:
    2009
  • 资助金额:
    $ 34.66万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.66万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 34.66万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 34.66万
  • 项目类别:
    Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 34.66万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 34.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 34.66万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
  • 批准号:
    2230829
  • 财政年份:
    2023
  • 资助金额:
    $ 34.66万
  • 项目类别:
    Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 34.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 34.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 34.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了